We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · February 06, 2020

Anti-TNF Treatment Is Associated With Decreased Survival in Steroid-Refractory, Ipilimumab- and Anti-PD-1-Treated Patients

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Association of Anti-TNF With Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1 Treated Patients in the Dutch Melanoma Treatment Registry
Clin. Cancer Res 2020 Jan 27;[EPub Ahead of Print], RJ Verheijden, AM May, CU Blank, MJB Aarts, FWPJ van den Berkmortel, AJM van den Eertwegh, JWB de Groot, MJ Boers-Sonderen, JJM van der Hoeven, GA Hospers, D Piersma, RS van Rijn, A Ten Tije, AA van der Veldt, G Vreugdenhil, MCT van Zeijl, MWJM Wouters, JBAG Haanen, E Kapiteijn, KP Suijkerbuijk

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading